Press releases

“The timely submission of our initial SDS microarray is yet another major step for the Company, advancing our efforts to demonstrate the effectiveness of MosaiQ in the transfusion diagnostics marketplace. The next steps include the submission of the initial SDS

Initial IH Microarray Approval in Europe Following the successful conclusion of its first EU field trial in July 2018 and the subsequent submission of the technical dossier for CE Mark approval in late September 2018, on April 30, 2019, the Company was informed that it had

Initial SDS Microarray – Field Trial Assay Performance Field trial results for the initial MosaiQ SDS Microarray used for the detection of CMV and Syphilis achieved the required clinical performance.  The field trial data was obtained by donor center testing